Introducing Velashape III. The Federal Food and Drug Administration (FDA) has cleared Syneron’s new noninvasive body shaping platform for marketing for abdominal circumferential reduction and other body-shaping applications such as cellulite treatments.
The FDA nod is based on a study of 42 patients who achieved an average abdominal circumference reduction of 2.6 cm after a single VelaShape III treatment protocol. Velashape III also has received the CE mark in the European Union.
As the third generation, VelaShape III builds on the original VelaShape elos technology, a proprietary blend of laser or light with bipolar radio frequency energy. The Vela brand includes VelaSmooth, VelaShape, and VelaShape II.
The new VelaShape III system is equipped with increased radio-frequency power of up to 150W, sophisticated real-time feedback mechanisms for consistent RF delivery independent of tissue variations, and a built-in, real time tissue surface temperature sensor. The system also offers a complete range of new tip configurations for various body locations. All these advanced features have been packaged into a sleek, state-of-the-art design with a highly optimized and user-friendly interface.
“We designed a sophisticated body-shaping platform that delivers visible outcomes in a single or small number of treatments, fits the doctor’s business needs, and leads the body-shaping category to the next level. Together with our physician partners and engineers, our customers now have a clinically proven solution that addresses what consumers are telling us they want,” says Shimon Eckhouse, PhD, chief executive officer of Syneron, in a news release.